Biomea Fusion (BMEA) Competitors

Biomea Fusion (NASDAQ:BMEA) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership.

Does the media refer more to BMEA or ITOS?

In the previous week, iTeos Therapeutics had 27 more articles in the media than Biomea Fusion. MarketBeat recorded 33 mentions for iTeos Therapeutics and 6 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.52 beat iTeos Therapeutics' score of 0.37 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iTeos Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor BMEA or ITOS?

Biomea Fusion received 15 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 75.38% of users gave iTeos Therapeutics an outperform vote while only 69.57% of users gave Biomea Fusion an outperform vote.

Company	Underperform	Outperform
Biomea Fusion	Outperform Votes 64 69.57%	Underperform Votes 28 30.43%
iTeos Therapeutics	Outperform Votes 49 75.38%	Underperform Votes 16 24.62%

Which has more risk and volatility, BMEA or ITOS?

Biomea Fusion has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.

Is BMEA or ITOS more profitable?

iTeos Therapeutics' return on equity of -20.11% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-118.90%	-93.66%
iTeos Therapeutics	N/A	-20.11%	-17.50%

Do analysts prefer BMEA or ITOS?

Biomea Fusion presently has a consensus target price of $22.60, indicating a potential upside of 1,339.49%. iTeos Therapeutics has a consensus target price of $17.86, indicating a potential upside of 113.86%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biomea Fusion is more favorable than iTeos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.08
iTeos Therapeutics	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

Which has stronger earnings and valuation, BMEA or ITOS?

iTeos Therapeutics has higher revenue and earnings than Biomea Fusion. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$117.25M	-$3.55	-0.44
iTeos Therapeutics	$35M	9.13	-$112.64M	-$3.04	-2.75

Do insiders and institutionals have more ownership in BMEA or ITOS?

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are owned by institutional investors. 27.6% of Biomea Fusion shares are owned by insiders. Comparatively, 12.5% of iTeos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

iTeos Therapeutics beats Biomea Fusion on 9 of the 17 factors compared between the two stocks.